Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 3 Issue 5, May 2022

CDH17-directed CAR T cells for solid tumors

CAR T cells developed to target Cadherin-17 (CDH17) eradicate neuroendocrine and gastrointestinal tumors in preclinical models, yet show no toxicity to normal tissues that also express CDH17.

See Feng et al.

Image: LetPub. Cover Design: Allen Beattie.

Editorial

  • Nature Cancer and the Nature journals are raising the standards on reporting on sex and gender in research. Starting this June, authors will be prompted to provide details on how sex and gender were considered in study design.

    Editorial

    Advertisement

Top of page ⤴

Comment & Opinion

  • As guidelines, therapies and literature on cancer variants expand, the lack of consensus variant interpretations impedes clinical applications. CIViC is a public-domain, crowd-sourced and adaptable knowledgebase of evidence for the clinical interpretation of variants in cancer, designed to reduce barriers to knowledge sharing and alleviate the variant-interpretation bottleneck.

    • Kilannin Krysiak
    • Arpad M. Danos
    • Malachi Griffith
    Comment
Top of page ⤴

News & Views

  • Patients with cancer are known to be at increased risk of infection and severe complications from COVID-19, with vaccination being key for their protection. A prospective study now evaluates the effect of vaccination against COVID-19 on the immune response mounted by patients with lymphoma.

    • Ariel Fromowitz
    • Amit Verma
    News & Views
  • Acute myeloid leukemia (AML) is characterized by distinct genetic and molecular alterations, including rearrangements in the mixed lineage leukemia (MLL) gene. A study now presents a therapeutic strategy for MLL-rearranged (MLL-r) AML that exploits a unique co-dependency on IKAROS and MENIN.

    • LaQuita M. Jones
    • Daniel T. Starczynowski
    News & Views
  • The lethality of prostate cancer is driven by its progression to a castration-resistant state. A new study identifies gremlin 1 (GREM1) as an agonist of fibroblast growth factor receptor 1 (FGFR1) that drives such progression when androgen receptor (AR) signaling is low, nominating GREM1 as a therapeutic target for prostate cancer with low AR activity.

    • Laura A. Sena
    • W. Nathaniel Brennen
    • John T. Isaacs
    News & Views
Top of page ⤴

Research Briefings

  • The transcription factor IKAROS is essential to maintaining a leukemogenic gene-expression profile mediated by transcription factors encoded by HOXA@ and MEIS1 in MLL1-rearranged (MLL-r) acute myeloid leukemia. Pharmacological degradation of IKAROS increases the effectiveness of inhibitors of the MLL1–MENIN protein–protein interaction, which leads to more-robust disruption of leukemogenic transcriptional networks and enhanced therapeutic benefit in preclinical models.

    Research Briefing
  • People with lymphoma have immune defects that compromise the immune response to vaccination. A prospective observational study of 457 people with lymphoma showed improvement in antibody and T cell responses after the third vaccine dose except in those who received anti-CD20 antibody therapy within a year prior to vaccination.

    Research Briefing
Top of page ⤴

Reviews

Top of page ⤴

Research

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Search

Quick links